• Research Interest
• Clinical Specialties
• Recent Publications
• Honors & Awards
• Training and Certifications
• Contact Information

Research Interest

Dr. Matthay is one of the world’s leading doctors and researchers in treatments for childhood cancer. She helps to direct the research of the Children’s Oncology Group to test new therapies for neuroblastoma, a cancer that often originates in the adrenal gland in the abdomen but also may begin in nerve tissue in the neck, chest or pelvis. In a recent study, she and her colleagues recently demonstrated that the outcome of neuroblastoma can be significantly improved by the use of innovative treatment that includes chemotherapy, bone marrow transplantation and the vitamin A derivative, 13-cis-retinoic acid. Dr. Matthay is currently the leader of a consortium of institutions testing novel targeted therapies for children with advanced neuroblastoma (www.nant.org).

Clinical Specialties

• Pediatric Cancer
• Pediatric Bone Marrow Transplant
• Pediatric Hematology

Recent Publications (selected)

• Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, Valteau-Couanet D, Hartmann O, Michon J. Early metastatic response by 123I-metaiodobenzylguanidine scintigraphy: correlation with overall response and event-free survival in stage 4 neuroblastoma. J. Clin Oncol. 2003; 21:2486-2491.
• Haas-Kogan D, Swift PS, Selch M, Haase G, Seeger RC, Gerbing R, Stram DO, Matthay KK. The role of radiotherapy for high-risk neuroblastoma: A Children’s Cancer Group study. Int J Radiat Oncol Biol Phys 2003; 56: 28-39.
• Dubois S, Messina J, Maris J, Huberty J, Glidden D, Veatch J, Charron M, Hawkins R, Matthay K. Hematologic toxicity of high dose 131I-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol, 2004; 22:2452-2460.
• Hayward K, Jeremy RJ, Jenkins S, Barkovich AJ, Gultekin SH, Kramer J, Crittenden M, Matthay KK. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: Relationship to MRI findings and anti-neuronal antibodies. J Pediatr 2001; 139:552-559.
• Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, Hawkins RA, Veatch J, Hasegawa B. Correlation of tumor and whole body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with 131I-metaiodobenzylguanidine (MIBG). J Nucl Med 2001; 42:1713-1721.

Honors & Awards (selected)

• 2000-01 Bourse: Henri de Rothschild at the Curie Institute for Professor in Residence
  
• 1997-2003 Bay Area’s Best Doctors, San Francisco Focus Magazine American Cancer Society Scholar Award .

Training & Certificates

• University of Pennsylvania, Medical Degree
• University of Colorado, Pediatric Residency
• UCSF Medical Center, Pediatric Hematology/Oncology Fellowship